One hormone target became two, then three, and the weight-loss pipeline is racing ahead. A neutral map of the multi-agonist contenders, CagriSema, MariTide, survodutide, retatrutide, and what sets them apart.
The weight-loss pipeline is increasingly built on multi-agonist drugs that target more than one hormone pathway. Leading candidates include CagriSema (about 20.4 percent trial weight loss), the once-monthly MariTide, survodutide, and the triple agonist retatrutide (up to about 28.7 percent). Most remain investigational, with FDA decisions and submissions pending.
The first GLP-1 drugs targeted a single hormone; the next generation stacks several pathways for greater effect.
May coverage offered a useful map of the contenders.
Conference and pipeline coverage carried into May outlined a crowded field of multi-agonist weight-loss candidates. CagriSema (cagrilintide plus semaglutide; Novo Nordisk) showed about 20.4 percent average weight loss in Phase 3 and has a regulatory submission pending. MariTide (maridebart cafraglutide; Amgen), a once-monthly injectable, showed roughly 12 to 16 percent in Phase 2. Survodutide, a dual glucagon/GLP-1 agonist, has Phase 3 results pending. Retatrutide (Eli Lilly), a triple GLP-1/GIP/glucagon agonist, showed up to about 28.7 percent, the highest reported in the class.
The throughline is mechanism: adding targets (amylin, GIP, glucagon) on top of GLP-1 appears to increase weight-loss effect, while introducing different dosing schedules and side-effect profiles. Most of these remain investigational, with timelines spread across the next several years, so the landscape is a preview rather than a current menu of options.
For consumers, the multi-agonist race promises more, and more varied, options ahead, from once-monthly dosing to higher potency, but choice also adds complexity. Higher efficacy can come with distinct tolerability and nutritional considerations. Importantly, most of these are not yet available, and trial percentages describe averages in studied populations. The right option, when approved, is an individual clinical decision, not a leaderboard pick.
Watch FDA submissions and decisions for CagriSema and the maturing data for retatrutide, MariTide, and survodutide, plus how dosing convenience and side effects compare. As the field expands, head-to-head data will become more valuable. For individuals, the practical stance is to follow approvals rather than trial buzz, and to make any treatment decision with a prescriber based on the specific approved evidence and personal health profile.